

**ASX/ Media Release**  
**20 April 2018**

## ASIC Form 484

**Sydney, Australia, 20 April 2018:** OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) is a medical device company focused on localised treatments for patients with pancreatic and liver cancer. Attached is ASIC Form 484 lodged with ASIC on 18 April 2018 for the Employee Share Buy Back relating to the Appendix 3F lodged with the ASX on 30 January 2018. The late lodgement of the Form 484 was due to an administrative oversight.

- ENDS -

Company	Media
<b>Mr Daniel Kenny</b> CEO & Managing Director E: <a href="mailto:daniel.kenny@oncosil.com.au">daniel.kenny@oncosil.com.au</a> T: +61 2 9223 3344	<b>Ben Walsh</b> WE Buchan E: <a href="mailto:bwalsh@buchanwe.com.au">bwalsh@buchanwe.com.au</a> M: 0411 520 012

### About OncoSil

OncoSil™ is a clinical-stage medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical trials with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch planned subject to approval.

The U.S Food and Drug Administration granted an Investigational Device Exemption (IDE) in July 2016 with approval to conduct a clinical study of the OncoSil™ device. The aim of the study will be to collect safety and effectiveness data required to support a Premarket Approval (PMA) application.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$2b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6<sup>th</sup> most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.

### Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any

assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

## Change to company details

### Company details

Company name

**ONCOSIL MEDICAL LTD**

Australian Company Number (ACN)

**113 824 141**

### Lodgement details

Who should ASIC contact if there is a query about this form?

Name

**Tomislav MILICEVIC**

### Signature

This form must be signed by a current officeholder of the company.

I certify that the information in this form is true and complete

Name

**Tomislav MILICEVIC**

Capacity

**Secretary**

Signature

Date signed

**18-04-2018**

## C1 Cancellation of shares

### Reason for cancellation

### Shares cancellation details

#### Reason for cancellation

ss.257H(3) Share buyback - Other buy-back type. A form 280 or 281 must be lodged at least 14 days, and no more than 1 year before the share buy-back can take place

The cancelled shares are listed below:

Share class code	Number of shares cancelled	Amount paid (cash or otherwise)	
ORD	7000000	0	

Earliest Date of cancellation      02-03-2018

## C3 Change to share structure

The updated details for this changed share class are shown in the table below.

Share class code	Full title if not standard	Total number of shares	Total amount paid on these shares	Total amount unpaid on these shares
ORD	ORDINARY SHARES	550541421	45359387.24	0.00

Earliest date of change      02-03-2018

## Change to company details

### Company details

Company name

**ONCOSIL MEDICAL LTD**

Australian Company Number (ACN)

**113 824 141**

### Lodgement details

Who should ASIC contact if there is a query about this form?

Name

**Tomislav MILICEVIC**

### Signature

This form must be signed by a current officeholder of the company.

I certify that the information in this form is true and complete

Name

**Tomislav MILICEVIC**

Capacity

**Secretary**

Signature

Date signed

**18-04-2018**

## C2 Issue of shares

New share issues are listed in the table below.

Share class code	Number of shares issued	Amount paid per share	Amount unpaid per share	
ORD	7000000	0	0	

Earliest Date of issue **02-03-2018**

## C3 Change to share structure

The updated details for this changed share class are shown in the table below.

Share class code	Full title if not standard	Total number of shares	Total amount paid on these shares	Total amount unpaid on these shares
ORD	ORDINARY SHARES	557541421	45359387.24	0.00

Earliest date of change **02-03-2018**